Cuba domestically marketed vaccine for lung cancer, one of the deadliest diseases among malignant tumors, clinical trials which yielded results "favorable," said local media on Monday.
CIGMAVAX-EGF, developed by the Center of Molecular Immunology, was registered in Cuba after being tested in over 1,000 patients without causing severe side effects.
"CIGMAVAX-EGF has the ability to turn advanced cancer a manageable chronic disease," the newspaper said quoting State Workers Gisela Gonzalez, head of the team that developed the vaccine.
Cuban authorities are pending registration in "other nations," said the specialist unclear which countries he meant.
Cancer is a major causes of death in Cuba.
The vaccine is based on the protein of the epidermal growth factor related to the processes of cell proliferation that goes awry in cancer patients, Gonzalez said.
The CIGMAVAX-EGF is applied in patients who have received radiotherapy or chemotherapy to help control tumor growth without toxicity associated explained.
Gonzalez said he may also be used as a chronic treatment that increases the expectations and quality of life. "
Cuba currently produces 38 drugs marketed in 40 countries.
of Cuban labs have gone vaccines against meningitis B and C, leptospirosis, typhoid fever and a synthetic vaccine against haemophilus influenzae type B, the leading cause of meningitis and other childhood infections.
Cuba has also made an anti-cervical cancer and cardiovascular problems recombinant. Public
.
0 comments:
Post a Comment